Noul brings AI cervical cancer screening technology to Indonesia
Noul, a Korean medtech firm specializing in artificial intelligence (AI)-driven diagnostic tools, has entered the Indonesian market through its first supply agreement for an automated cervical cancer screening system as the Southeast Asian nation works to scale up preventive care. The company said Thursday it signed the agreement with an Indonesian medical device distributor and plans to supply…
Korean medical technology company Noul has entered the Indonesian market by securing an agreement to supply an automated cervical cancer screening system to local medical institutions and laboratory networks. The miLab CER units, which utilize artificial intelligence for diagnostic purposes, will be provided to at least 50 healthcare facilities over a three-year period.
Noul plans to initially focus on working with hospitals, screening centers, and laboratory networks before exploring opportunities within Indonesia's public procurement market. The company has already secured regulatory approvals for miLab CER in several Southeast Asian countries, including Vietnam and the Philippines, which will serve as a foundation for further expansion throughout the region.
Indonesia, with a population of approximately 280 million people, represents Southeast Asia's largest healthcare market, and Noul believes cervical cancer poses a significant burden on women in the country.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Noul brings AI cervical cancer screening technology to Indonesia koreatimes.co.kr
